Logo

Foundation Medicine FoundationOne Monitor

Jun 02, 2023

Roche subsidiary Foundation Medicine has launched its FoundationOne Monitor test for research use in retrospective studies. The tissue-naive circulating tumor DNA monitoring assay is available for biopharmaceutical customers and uses the firm's ctDNA tumor fraction biomarker. The test quantifies ctDNA tumor fraction at each timepoint and offers molecular response insights to complement standard imaging in early-phase clinical research, the company said. It can also assess resistance to therapy across more than 300 genes. The assay is currently in development for clinical use.

Breaking News
The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.